By Steven Scheer TEL AVIV (Reuters) – Teva Pharmaceutical Industries expects to finalise an opioid settlement in the United States by year-end and start paying in 2023, its chief executive said on Sunday, while confirming he was unlikely to renew his contract next year. After years of negotiations, Israel-based Teva in July proposed a $4.35 billion nationwide settlement – mostly cash and partly medicines that will amount to $300 million to $400 million over 13 years – to resolve its opioid lawsuits. U.S. states, cities and counties filed more than 3,000 lawsuits against opioid manufacturers, d…